Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 13th Oct 2014 09:32

Amino Technologies: Northland Capital upgrades to buy with a target price of 100p.Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p.Associated British Foods: Societe Generale upgrades to buy with a target price of 2950p.AstraZeneca: Jefferies raises target price from 4500p to 5000p upgrading to buy.Betfair Group: Numis reduces target price from 1250p to 940p downgrading to reduce.Bodycote: Investec cuts target price from 775p to 750p and stays with its buy recommendation.Brammer: Investec cuts target price from 435p to 400p, while keeping a buy recommendation.Brown (N) Group: N+1 Singer reduces target price from 585p to 390p, while staying with its buy recommendation. Jefferies cuts target price from 540p to 406p and reiterates a buy recommendation.BTG: Investec raises target price from 728p to 832p staying with its buy recommendation.bwin.party: Numis cuts target price from 200p to 180p and keeps a buy recommendation.Coca-Cola HBC: Credit Suisse reduces target price from 1500p to 1400p, while maintaining its neutral rating.Dialight: Investec reduces target price from 910p to 850p downgrading to sell.Domino Printing: Investec cuts target price from 650p to 615p keeping an add rating.Eagle Eye: Panmure Gordon initiates with a target price of 229p and a buy recommendation.Fenner: Investec cuts target price from 320p to 270p and retains a sell recommendation.Ferrexpo: Cantor Fitzgerald reduces target price from 250p to 120p maintaining a buy recommendation.GKN: Investec cuts target price from 380p to 330p, while upgrading from add to buy.GlaxoSmithKline: Jefferies ups target price from 1385p to 1400p and retains a hold recommendation.Glencore: Canaccord Genuity initiates with a target price of 400p and a buy recommendation.Halma: Investec lowers target price from 635p to 630p and maintains a buy recommendation.Hellermann Tyton: Investec lowers target price from 305p to 300p and retains a hold recommendation.IMI: Investec reduces target price from 1560p to 1425p and keeps a buy recommendation.IMImobile: WH Ireland ups target price from 175p to 187p and retains a buy recommendation.Jupiter Fund Management: JP Morgan cuts target price from 465p to 400p staying with an overweight rating. Espirito Santo cuts target price from 489p to 469p leaving its buy recommendation unaltered.Ladbrokers: Numis reduces target price from 150p to 100p downgrading to reduce.Laird: Investec lowers target price from 260p to 250p leaving its sell recommendation unchanged.Melrose: Investec shifts target price from 332p to 335p and keeps a buy recommendation.Molins: Panmure Gordon reduces target price from 250p to 165p and stays with its buy recommendation.Morgan Advanced Materials: Investec lowers target price from 345p to 335p reiterating its buy recommendation.Oxford Instruments: Investec reduces target price from 1520p to 1405p and reiterates a buy recommendation.Paragon Group: JP Morgan ups target price from 396p to 420p and leaves its overweight rating unchanged.Playtech: Numis cuts target price from 700p to 665p and reiterates a hold recommendation.Renishaw: Investec reduces target price from 1900p to 1775p keeping a buy recommendation.Rotork: Investec reduces target price from 2840p to 2610p retaining its add rating.Smith (DS): Investec cuts target price from 380p to 350p and stays with its buy recommendation.Smith & Nephew: Investec reduces target price from 1100p to 1023p and downgrades from add to hold.Smith (WH): Canaccord Genuity initiates with a target price of 1225p and a buy recommendation.Spectris: Investec reduces target price from 2580p to 2380p and maintains a buy recommendation.Spirax-Sarco: Investec reduces target price from 2920p to 2810p and stays with its add rating.TSB: Investec shifts target price from 290p to 295p upgrading from hold to buy.Vedanta Resources: Canaccord Genuity initiates with a target price of 1020p and a hold recommendation. JP Morgan lowers target price from 1140p to 1130p and retains its neutral rating.Vesuvius: Investec cuts target price from 485p to 450p and reiterates an add rating.Vitec Group: Investec cuts target price from 790p to 740p maintaining a buy recommendation.Weir Group: Investec raises target price from 2400p to 2525p, but still recommends selling.William Hill: Numis reduces target price from 500p to 400p downgrading to add.888 Holdings: Numis cuts target price from 220p to 175p and keeps a buy recommendation.32Red: Numis lowers target price from 100p to 80p, while retaining its buy recommendation.
More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.